| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/29/2004 | EP1461034A1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
| 09/29/2004 | EP1461020A1 Synthesis of small particles |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1460999A2 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 09/29/2004 | EP1392700B1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta(a)naphthalene |
| 09/29/2004 | EP1389202B1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 09/29/2004 | EP1189905B1 Substituted heterocycle fused gamma-carbolines |
| 09/29/2004 | EP1189881B1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 09/29/2004 | EP1123295B1 Bicyclic nitrogen heterocycles |
| 09/29/2004 | EP1114033B1 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 09/29/2004 | EP1090116B1 Transgenic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 09/29/2004 | EP1090019B1 Adenosine derivatives |
| 09/29/2004 | EP1019378B1 Hypoglycemic and hypolipidemic compounds |
| 09/29/2004 | EP1019040B1 Aryl ureas for the treatment of inflammatory or immunomodulatory diseases |
| 09/29/2004 | EP1003503B1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/29/2004 | EP0999832B1 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols |
| 09/29/2004 | EP0993439B1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 09/29/2004 | EP0914146B1 Morphogen treatment for chronic renal failure |
| 09/29/2004 | CN1533391A Tricyclic compounds and their uses |
| 09/29/2004 | CN1533388A Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 09/29/2004 | CN1533387A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/29/2004 | CN1533382A 哌嗪衍生物 Piperazine derivatives |
| 09/29/2004 | CN1533374A Substitutled cyclohexane-1,4-diamine derivatives |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533283A Use of osteopontin for treatment and/or prevention of neurologic diseases |
| 09/29/2004 | CN1533280A Carbohydrate modifying agent and drinks containing the same |
| 09/29/2004 | CN1533277A Preventives or remedies for diseases caused by e NOS expression |
| 09/29/2004 | CN1531948A Medicine for treating diabetes and its producing method |
| 09/29/2004 | CN1531940A Nutrition liquid for regulating physiological funnction |
| 09/29/2004 | CN1531926A Reinforced type lecithin capsule |
| 09/29/2004 | CN1531870A Human needed amino acid serial products |
| 09/29/2004 | CN1168738C Biotin derivatives |
| 09/29/2004 | CN1168726C Novel vitamin D analogues |
| 09/29/2004 | CN1168720C Aryl alkanoylpyridazines compounds |
| 09/29/2004 | CN1168719C 6-phenylpyridyl-2-amine derivatives and pharmaceutical composition and use |
| 09/29/2004 | CN1168693C Substituted phenols and thiophenols useful as antioxidant agents |
| 09/29/2004 | CN1168499C Medicament for optimising mucosal viscosity and stimulating intestinal function |
| 09/29/2004 | CN1168498C Child 'xuebao' chewing tablet and preparing process thereof |
| 09/29/2004 | CN1168496C Powder snuff of insulin for administration of lung and its preparing process |
| 09/29/2004 | CN1168462C Oral liquid capable of reducing blood fat and improving symptom of myocardial ischemia and infarction |
| 09/29/2004 | CN1168451C Use of thiazolidinedione and sulphonylurea composition in preparing medicine for treating diabetes |
| 09/28/2004 | US6797290 Oral administration of chitosan and glycomacropeptide (gmp), wherein the chitosan and gmp are in other than a cationic gum or polysaccharide/protein complex; cholecystokinin (cck) stimulant; anticholesterol, -lipemic agents |
| 09/28/2004 | US6797287 Administering a formulation containing phaseolamin (white kidney bean extract) and a mineral, such as chromium or vanadium or both for controlling carbohydrate cravings |
| 09/28/2004 | US6797265 Therapy for metabolism disorders; gene therapy |
| 09/28/2004 | US6797263 Compositions and methods for achieving immune suppression |
| 09/28/2004 | CA2299013C Neuropeptide y antagonists |
| 09/28/2004 | CA2109028C Stabilized sorbic acid or salt thereof |
| 09/23/2004 | WO2004081046A2 Human monoclonal antibodies against apociii and their use in the therapy of atherosclerosis |
| 09/23/2004 | WO2004081039A1 Novel protein and its dna |
| 09/23/2004 | WO2004081011A1 Immunomodulating heterocyclic compounds |
| 09/23/2004 | WO2004081009A1 Quinazoline derivatives as tgf-beta inhibitors |
| 09/23/2004 | WO2004081004A1 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| 09/23/2004 | WO2004081003A1 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia |
| 09/23/2004 | WO2004081002A1 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| 09/23/2004 | WO2004081001A1 Novel 2-pyridinecarboxamide derivatives |
| 09/23/2004 | WO2004080990A1 C-glycoside derivatives and salts thereof |
| 09/23/2004 | WO2004080968A1 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 09/23/2004 | WO2004080964A1 Indole derivatives useful for the treatment of diseases |
| 09/23/2004 | WO2004080947A1 Imino ether derivative compounds and drugs containing the compounds as the active ingredient |
| 09/23/2004 | WO2004080485A1 Preventive/remedy for diseases in upper digestive tract |
| 09/23/2004 | WO2004080484A1 Adipocyte differentiation inhibitor |
| 09/23/2004 | WO2004080482A2 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
| 09/23/2004 | WO2004080470A1 Preventive/remedy for obesity |
| 09/23/2004 | WO2004080469A1 Supplemental food for recovery from hypoglycemic symptoms |
| 09/23/2004 | WO2004080462A1 c-Kit KINASE INHIBITOR |
| 09/23/2004 | WO2004080452A1 Remedies for retinal diseases |
| 09/23/2004 | WO2004080450A2 Combined use of a fibrate and orlistat for the treatment of obesity |
| 09/23/2004 | WO2004080448A2 Use of nep-associated molecules for treating non-immunogenic, non-hypertensive civilisation diseases |
| 09/23/2004 | WO2004080401A2 Oral insulin therapies and protocol |
| 09/23/2004 | WO2004080209A1 Serum remnant-like lipoprotein concentration regulator |
| 09/23/2004 | WO2004041258A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 09/23/2004 | WO2004035082A3 Proteins involved in the regulation of energy homeostasis |
| 09/23/2004 | WO2004010944A3 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications |
| 09/23/2004 | WO2003061681A3 Proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 09/23/2004 | US20040186299 such as 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylic acid; for lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes; for increasing leptin levels with no liver toxicity |
| 09/23/2004 | US20040186295 G protein-coupled receptors activators such as 2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]pyridine, used as analgesics, anxiolytic, antidepressants, and for prophylaxis of psychological disorders |
| 09/23/2004 | US20040186290 transferase enzyme modulators such as 2-(6-Chloropyridin-3-yl)-3-cyclopentyl-N-thiazol-2-ylpropionamide, used for prophylaxis of hyperglycemia and diabetes |
| 09/23/2004 | US20040186178 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/23/2004 | US20040186162 preparation of the amorphous inhibitor and its hydrates of desired particle size which comprises dissolving the inhibitor in a hydroxylic solvent (methanol), then removing the solvent by freeze-drying |
| 09/23/2004 | US20040186159 used to treat glaucomatous optic neuropathy and/or lower and control intraocular pressure (IOP) associated with normal-tension glaucoma, ocular hypertension, and/or glaucoma in warm blooded animals, including man |
| 09/23/2004 | US20040186154 treating or preventing a hypercholesterolemia-related or an inflammation-related condition ; apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug; kits |
| 09/23/2004 | US20040186153 Pharmaceutical use of N-carbamoylazole derivatives |
| 09/23/2004 | US20040186145 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 09/23/2004 | US20040186134 Inhibitors of Factor Xa are useful as anticoagulants in the treatment of cardiovascular disorders associated with thromboses; e.g., 1,1-dimethylethyl 1-[1-(-2-(-3-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonylamino]-2-oxo-piperidin-1-yl)-acetyl)-pyrrolidin-2- yl-methyl]-pyrrolidin-3-yl}-methyl-carbamate |
| 09/23/2004 | US20040186133 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system |
| 09/23/2004 | US20040186127 E.g., 7-(5-(2-(cyclohexylmethylamino)ethyl)indol-2-yl), 2-methyl-3H-imidazo(4,5-b)pyridine; antiinflammatory agents; antiproliferative agents; autoimmune diseases; reperfusion injuries; osteoporosis; bone disorders; antimetastasis agents |
| 09/23/2004 | US20040186126 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 09/23/2004 | US20040186113 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 09/23/2004 | US20040186109 piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction |
| 09/23/2004 | US20040186099 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185508 Methods and reagents for modulating cholesterol levels |
| 09/23/2004 | US20040185129 Salvia hispanica l (chia) in the management and treatment of cardiovascular disease diabetes and asociated risk factors |
| 09/23/2004 | US20040185125 Daily administering a mixture of zinc salt, cyclo-Hispro (soybean protein product), arachidonic acid; treating hypertension, high cholesterol, weight control; nutritional supplements, foods |
| 09/23/2004 | US20040185122 Selective COX-2 inhibition from edible plant extracts |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | DE10311984A1 Using neutral endopeptidase-associated molecules for treatment, diagnosis, prophylaxis and monitoring of eating and metabolic disorders and dementia, also for drug development |
| 09/23/2004 | CA2522818A1 Pharmaceutical preparations comprising acid-stabilised insulin |
| 09/23/2004 | CA2518986A1 Imino ether derivative compounds and drugs containing the compounds as the active ingredient |
| 09/23/2004 | CA2518216A1 Oral insulin therapies and protocol |